Tap into the power of unmatched scientific expertise and the world's leading computerised tests of cognition.
CANTAB® has been used in over 1000 peer-reviewed research studies, in more than 100 pharma clinical trials and to test cognitive functioning in an estimated 300,000 people across the world.
Cognitive impairment is frequently observed in patients with mood disorder, affecting around two-thirds of patients with depression and predicting poor response to treatment. We investigated whether cognitive impairment should be considered a core feature of depression that may be a valuable target for future pharmacological treatments.
Read more